A new era in ocular therapeutics: advanced drug delivery systems for uveitis and neuro-ophthalmologic conditions
KY Wu, K Tan, D Akbar, MY Choulakian, SD Tran - Pharmaceutics, 2023 - mdpi.com
The eye's intricate anatomical barriers pose significant challenges to the penetration,
residence time, and bioavailability of topically applied medications, particularly in managing …
residence time, and bioavailability of topically applied medications, particularly in managing …
Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature
C Iovino, R Mastropasqua, M Lupidi, D Bacherini… - Pharmaceutics, 2020 - mdpi.com
Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical
industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the …
industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the …
[HTML][HTML] Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis
T Tao, S Yang, D He, Z Li, B Chen, L Zhu, W Su - Clinical Immunology, 2023 - Elsevier
To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex®, as an
adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were …
adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were …
Real-life efficacy, safety, and use of dexamethasone intravitreal implant in posterior segment inflammation due to non-infectious uveitis (LOUVRE 2 Study)
B Bodaghi, AP Brézin, M Weber, C Delcourt… - Ophthalmology and …, 2022 - Springer
Introduction To evaluate real-life efficacy, safety, and treatment patterns with the
dexamethasone intravitreal implant (DEX) in posterior segment inflammation due to non …
dexamethasone intravitreal implant (DEX) in posterior segment inflammation due to non …
Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm
O Shahzad, N Thompson, G Clare… - … in medical oncology, 2021 - journals.sagepub.com
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors
(CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated …
(CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated …
Treatment of non-infectious posterior uveitis with dexamethasone intravitreal implants in a real-world setting
F Butt, H Devonport - Clinical Ophthalmology, 2023 - Taylor & Francis
Purpose The present study aimed to assess the efficacy and safety associated to the
treatment of patients with non-infectious posterior uveitis with intravitreal dexamethasone …
treatment of patients with non-infectious posterior uveitis with intravitreal dexamethasone …
The double-edged sword of inflammation in inherited retinal degenerations: clinical and preclinical evidence for mechanistically and prognostically impactful but …
K Sarici, A Vyas, A Iannaccone - Frontiers in Cell and Developmental …, 2023 - frontiersin.org
We present retrospective data from our clinical research efforts of the past several years
alongside a review of past and current clinical and preclinical data independently by several …
alongside a review of past and current clinical and preclinical data independently by several …
Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab
Y Huang, F Khan, NV Saraiya, OS Punjabi… - Journal of …, 2023 - journals.lww.com
Checkpoint inhibition targeting programmed cell-death protein 1 has demonstrated efficacy
for a wide range of indications including cutaneous malignancy. However, immune-related …
for a wide range of indications including cutaneous malignancy. However, immune-related …
Intravitreal dexamethasone implants for refractory macular edema in eyes with noninfectious uveitis
Macular edema (ME) is a common cause of visual loss among eyes with uveitis, and its
management can be challenging. Steroids are an effective treatment for ME, and intravitreal …
management can be challenging. Steroids are an effective treatment for ME, and intravitreal …
[HTML][HTML] Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
J Deng, WT Sun, H Ai, LP Wang - International Journal of …, 2023 - ncbi.nlm.nih.gov
AIM To evaluate the long-term results of patients with chronic uveitis-induced cataract by
phacoemulsification with IOL implantation and intravitreal injection of dexamethasone (DEX) …
phacoemulsification with IOL implantation and intravitreal injection of dexamethasone (DEX) …